Alzheimer’s

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is ending 2025 in rare biotech air. The RNA interference (RNAi) specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a

9 December 2025

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced

8 December 2025

Biotech Stocks · Clinical Trials · FDA Approvals · NASDAQ:ARWR · Pharmaceutical News · Stock Performance

NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

Key takeaways NVO stock today: price and trading snapshot (Nov. 25, 2025) As of late‑afternoon trading on Tuesday, November 25, 2025, Novo Nordisk A/S American Depositary Receipts (ADR), ticker NVO on the NYSE, were changing hands at about $47.08, up

25 November 2025

Drug Research · Novo Nordisk · Pharmaceuticals · Stock Market · Weight Loss

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen Inc. (NASDAQ: BIIB) shares surged to fresh 52‑week highs on Monday, November 24, 2025, as investors reacted to a high‑profile Alzheimer’s drug failure at Novo Nordisk and a new immunology partnership with Dayra Therapeutics. By the closing bell, BIIB

24 November 2025

Alzheimer’s · Biogen · Biotech · Investing · Stock Market

Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Danish pharma giant Novo Nordisk is under intense pressure today after its high‑profile Alzheimer’s trials for semaglutide failed, sending the stock to multi‑year lows and capping a brutal year for NVO shareholders. Novo Nordisk stock today: how far has NVO

24 November 2025

Drug Development · Financial Analysis · Investing News · NYSE:NVO · Pharmaceuticals · Stock Market

InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals Inc. (NASDAQ: INM) is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name. On

20 November 2025

Alzheimer’s Disease · Biotechnology · Medical Research · NASDAQ:INM · Pharmaceutical News · Stock Market

Anavex Life Sciences (AVXL) Stock Plunges After EMA Issues Negative Trend Vote on Alzheimer’s Drug

Anavex Life Sciences (NASDAQ: AVXL) tumbled on November 14, 2025 after Europe’s drug regulator delivered a negative trend vote on its Alzheimer’s candidate blarcamesine. The company plans a CHMP re-examination and a fresh meeting with the FDA. Here’s what happened

14 November 2025

Alzheimer’s Disease · Biotech News · Investment Analysis · NASDAQ:AVXL · Pharmaceuticals · Stock Market

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

LLY Stock Skyrockets, Then Dips on Pricing Jitters Eli Lilly’s stock has been on a tear in 2025, powered by optimism around its new drug innovations. Shares surged dramatically at the start of October – leaping from about $726 at

17 October 2025

Alzheimer’s Research · Investment Analysis · NYSE:LLY · Obesity Treatment · Pharmaceuticals · Stock Market

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

GLP-1 Receptor Agonists and Neurodegenerative Diseases in 2025 GLP-1 receptor agonists like semaglutide (Ozempic®) are typically given via a weekly injection pen. Originally developed for diabetes and obesity, these drugs are now being studied for their effects on the brain.

10 September 2025

Alzheimer’s · GLP-1 Drugs · Medicine · Neurodegenerative Diseases · NYSE:NVO · Weight Loss

Mars’ Core Revealed, “Pristine” Galaxy Spotted, Alzheimer’s Test Hope, and a Quantum Leap – Science News Roundup (Sept 4–5, 2025)

Space & Astronomy Marsquakes Confirm Mars Has a Solid Metal Core Seismic readings from NASA’s InSight Mars lander have revealed that Mars possesses a solid inner core, much like Earth’s. A Chinese-led team analyzed faint marsquake waves and found Mars’

5 September 2025

Astronomy · Mars · Neuroscience · Quantum Physics · Science News

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Key Facts Scientific Breakthroughs & New Research Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests

30 August 2025

Biotech · Global News · Health · Medicine · NASDAQ:CYTK · NYSE:GSK · NYSE:SNY · Public Health

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

Drug Approvals & Clinical Trial Results Updated COVID Boosters Get Narrow Nod: The U.S. FDA approved new fall COVID-19 booster shots from Pfizer/BioNTech and Moderna on August 27 – but with strict eligibility limits. Only adults 65+ and younger people

29 August 2025

COVID-19 · Global Health · Health News · Medical Breakthroughs · NASDAQ:AMLX · NASDAQ:OTLK · NASDAQ:PRTA · NYSE:NVO · NYSE:WBA · Pharmaceuticals